Testimonials
Pfizer
Pfizer is delighted to receive approval from the U.S. Food and Drug Administration (FDA) for BESPONSA® (inotuzumab ozogamicin) for use in a pediatric population. This approval will provide pediatric patients with an additional treatment option in an area of high unmet need. We are grateful to the Innovative Therapies for Children with Cancer (ITCC) Consortium for their longstanding collaboration as sponsors of the clinical study supporting the approval. This milestone wouldn’t have been possible without their diligence as researchers and commitment to pediatric acute lymphoblastic leukemia (ALL) patients.
Jaime Verdú Amorós
Hospital Clínico Universitario Valencia
The ITCC fellowship was an amazing opportunity to improve my clinical skills in the field of early phase clinical trials and drug development. It was an intensive period dealing with sick patients, new drugs, clinical and ethical challenges. It was also an opportunity for a fruitful professional exchange and scientific production. I would strongly recommend this enriching experience to colleagues interested in clinical research."